Telix Pharmaceuticals Limited has acquired Sacramento, California-based Optimal Tracers.
Optimal Tracers is a division of Northern California PET Imaging Center, a not-for-profit business providing clinical and clinical trial imaging services in northern California. Optimal Tracers provides manufacturing and development radiochemistry services in support of academic and pharmaceutical research activities.
Telix Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is headquartered in Australia with commercial operations in the U.S., Europe (Belgium and Switzerland) and Japan.
Telix will fund the acquisition from operational cash flow. Terms of the deal were not disclosed.
According to the LevinPro HC database, this was the seventh MRI deal of 2022. This compares with three MRI transactions recorded between January 1, 2021, and November 15, 2021.
